{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T20:41:45Z","timestamp":1788295305861,"version":"build-2803163510"},"reference-count":284,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"DOI":"10.1007\/s11912-025-01721-y","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T03:52:33Z","timestamp":1761969153000},"page":"1312-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Expendables: Overlooked Medications with Anti-Cancer Properties"],"prefix":"10.1007","volume":"27","author":[{"given":"Anagha J.","family":"Deshpande","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razelle","family":"Kurzrock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"1721_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1721_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd3078","volume":"9","author":"SM Paul","year":"2010","unstructured":"Paul SM, Mytelka DS, Dunwiddie CT, et al. How to improve R&D productivity: the pharmaceutical industry\u2019s grand challenge. Nat Rev Drug Discov. 2010;9:203\u201314.","journal-title":"Nat Rev Drug Discov"},{"key":"1721_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18:41\u201358.","journal-title":"Nat Rev Drug Discov"},{"key":"1721_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-020-0714-y","volume":"12","author":"JJ Adashek","year":"2020","unstructured":"Adashek JJ, Kato S, Lippman SM, Kurzrock R. The paradox of cancer genes in non-malignant conditions: implications for precision medicine. Genome Med. 2020;12:16.","journal-title":"Genome Med"},{"key":"1721_CR5","doi-asserted-by":"crossref","unstructured":"Kato S, Lippman SM, Flaherty KT, Kurzrock R. The conundrum of genetic drivers in benign conditions. J Natl Cancer Inst. 2016;108.","DOI":"10.1093\/jnci\/djw036"},{"key":"1721_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.medj.2024.04.008","volume":"5","author":"M Nikanjam","year":"2024","unstructured":"Nikanjam M, Wells K, Kato S, Adashek JJ, Block S, Kurzrock R. Reverse repurposing: potential utility of cancer drugs in nonmalignant illnesses. Med. 2024;5:689\u2013717.","journal-title":"Med"},{"key":"1721_CR7","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/534314a","volume":"534","author":"N Nosengo","year":"2016","unstructured":"Nosengo N. Can you teach old drugs new tricks? Nature. 2016;534:314\u20136.","journal-title":"Nature"},{"key":"1721_CR8","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41573-019-0046-z","volume":"19","author":"A Huang","year":"2020","unstructured":"Huang A, Garraway LA, Ashworth A, Weber B. Synthetic lethality as an engine for cancer drug target discovery. Nat Rev Drug Discov. 2020;19:23\u201338.","journal-title":"Nat Rev Drug Discov"},{"key":"1721_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nrg.2017.74","volume":"19","author":"G Rancati","year":"2018","unstructured":"Rancati G, Moffat J, Typas A, Pavelka N. Emerging and evolving concepts in gene essentiality. Nat Rev Genet. 2018;19:34\u201349.","journal-title":"Nat Rev Genet"},{"key":"1721_CR10","doi-asserted-by":"publisher","first-page":"14807","DOI":"10.1073\/pnas.96.26.14807","volume":"96","author":"J Zhu","year":"1999","unstructured":"Zhu J, Gianni M, Kopf E, et al. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic raralpha fusion proteins. Proc Natl Acad Sci U S A. 1999;96:14807\u201312.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1721_CR11","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/S0092-8674(00)80708-4","volume":"97","author":"LP Freedman","year":"1999","unstructured":"Freedman LP. Increasing the complexity of coactivation in nuclear receptor signaling. Cell. 1999;97:5\u20138.","journal-title":"Cell"},{"key":"1721_CR12","doi-asserted-by":"publisher","first-page":"4227","DOI":"10.1091\/mbc.e10-05-0449","volume":"21","author":"MC Geoffroy","year":"2010","unstructured":"Geoffroy MC, Jaffray EG, Walker KJ, Hay RT. Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies. Mol Biol Cell. 2010;21:4227\u201339.","journal-title":"Mol Biol Cell"},{"key":"1721_CR13","first-page":"57","volume":"21","author":"SH Woo","year":"2002","unstructured":"Woo SH, Park IC, Park MJ, et al. Arsenic trioxide induces apoptosis through a reactive oxygen species-dependent pathway and loss of mitochondrial membrane potential in HeLa cells. Int J Oncol. 2002;21:57\u201363.","journal-title":"Int J Oncol"},{"key":"1721_CR14","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1586\/14737140.1.1.53","volume":"1","author":"M Raderer","year":"2001","unstructured":"Raderer M, Isaacson PG. Extranodal lymphoma of MALT-type: perspective at the beginning of the 21st century. Expert Rev Anticancer Ther. 2001;1:53\u201364.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1721_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1136\/gut.53.1.34","volume":"53","author":"W Fischbach","year":"2004","unstructured":"Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut. 2004;53:34\u20137.","journal-title":"Gut"},{"key":"1721_CR16","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1093\/jnci\/89.18.1350","volume":"89","author":"A Neubauer","year":"1997","unstructured":"Neubauer A, Thiede C, Morgner A, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89:1350\u20135.","journal-title":"J Natl Cancer Inst"},{"key":"1721_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1093\/annonc\/mdh300","volume":"15","author":"V Eleutherakis-Papaiakovou","year":"2004","unstructured":"Eleutherakis-Papaiakovou V, Bamias A, Dimopoulos MA. Thalidomide in cancer medicine. Ann Oncol. 2004;15:1151\u201360.","journal-title":"Ann Oncol"},{"key":"1721_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1182\/blood-2004-09-3679","volume":"106","author":"T Yabu","year":"2005","unstructured":"Yabu T, Tomimoto H, Taguchi Y, Yamaoka S, Igarashi Y, Okazaki T. Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood. 2005;106:125\u201334.","journal-title":"Blood"},{"key":"1721_CR19","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.3892\/ijo.2015.3155","volume":"47","author":"YT Huang","year":"2015","unstructured":"Huang YT, Cheng CC, Chiu TH, Lai PC. Therapeutic potential of thalidomide for gemcitabine-resistant bladder cancer. Int J Oncol. 2015;47:1711\u201324.","journal-title":"Int J Oncol"},{"key":"1721_CR20","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1200\/JCO.2005.03.8851","volume":"24","author":"P Richardson","year":"2006","unstructured":"Richardson P, Anderson K. Thalidomide and dexamethasone: a new standard of care for initial therapy in multiple myeloma. J Clin Oncol. 2006;24:334\u20136.","journal-title":"J Clin Oncol"},{"key":"1721_CR21","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1158\/0008-5472.CAN-16-2400","volume":"77","author":"WS Henry","year":"2017","unstructured":"Henry WS, Laszewski T, Tsang T, et al. Aspirin suppresses growth in PI3K-mutant breast cancer by activating AMPK and inhibiting mTORC1 signaling. Cancer Res. 2017;77:790\u2013801.","journal-title":"Cancer Res"},{"key":"1721_CR22","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.cellsig.2008.02.004","volume":"20","author":"MR Pan","year":"2008","unstructured":"Pan MR, Chang HC, Hung WC. Non-steroidal anti-inflammatory drugs suppress the ERK signaling pathway via block of Ras\/c-Raf interaction and activation of MAP kinase phosphatases. Cell Signal. 2008;20:1134\u201341.","journal-title":"Cell Signal"},{"key":"1721_CR23","doi-asserted-by":"publisher","first-page":"3820","DOI":"10.1158\/0008-5472.CAN-19-0762","volume":"79","author":"LM Lichtenberger","year":"2019","unstructured":"Lichtenberger LM, Vijayan KV. Are platelets the primary target of aspirin\u2019s remarkable anticancer activity? Cancer Res. 2019;79:3820\u20133.","journal-title":"Cancer Res"},{"key":"1721_CR24","doi-asserted-by":"publisher","first-page":"11301","DOI":"10.1073\/pnas.95.19.11301","volume":"95","author":"J Ruschoff","year":"1998","unstructured":"Ruschoff J, Wallinger S, Dietmaier W, et al. Aspirin suppresses the mutator phenotype associated with hereditary nonpolyposis colorectal cancer by genetic selection. Proc Natl Acad Sci U S A. 1998;95:11301\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1721_CR25","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrc3004","volume":"11","author":"LJ Gay","year":"2011","unstructured":"Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011;11:123\u201334.","journal-title":"Nat Rev Cancer"},{"key":"1721_CR26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/S1470-2045(12)70112-2","volume":"13","author":"AM Algra","year":"2012","unstructured":"Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol. 2012;13:518\u201327.","journal-title":"Lancet Oncol"},{"key":"1721_CR27","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1016\/S0959-8049(02)00128-4","volume":"38","author":"S Touhey","year":"2002","unstructured":"Touhey S, O\u2019Connor R, Plunkett S, Maguire A, Clynes M. Structure-activity relationship of indomethacin analogues for MRP-1, COX-1 and COX-2 inhibition. Identification of novel chemotherapeutic drug resistance modulators. Eur J Cancer. 2002;38:1661\u201370.","journal-title":"Eur J Cancer"},{"key":"1721_CR28","doi-asserted-by":"publisher","first-page":"6584","DOI":"10.3390\/molecules18066584","volume":"18","author":"YC Guo","year":"2013","unstructured":"Guo YC, Chang CM, Hsu WL, et al. Indomethacin inhibits cancer cell migration via attenuation of cellular calcium mobilization. Molecules. 2013;18:6584\u201396.","journal-title":"Molecules"},{"key":"1721_CR29","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.canlet.2019.05.008","volume":"457","author":"CC Lin","year":"2019","unstructured":"Lin CC, Suen KM, Stainthorp A, et al. Targeting the Shc-EGFR interaction with indomethacin inhibits MAP kinase pathway signalling. Cancer Lett. 2019;457:86\u201397.","journal-title":"Cancer Lett"},{"key":"1721_CR30","doi-asserted-by":"publisher","first-page":"8238","DOI":"10.1074\/jbc.RA118.004415","volume":"294","author":"S Mazumder","year":"2019","unstructured":"Mazumder S, De R, Debsharma S, et al. Indomethacin impairs mitochondrial dynamics by activating the PKCzeta-p38-DRP1 pathway and inducing apoptosis in gastric cancer and normal mucosal cells. J Biol Chem. 2019;294:8238\u201358.","journal-title":"J Biol Chem"},{"key":"1721_CR31","doi-asserted-by":"publisher","first-page":"2752","DOI":"10.1001\/jama.1978.03290250056030","volume":"240","author":"JM Wallace","year":"1978","unstructured":"Wallace JM, Gill DP. Prazosin in the diagnosis and treatment of pheochromocytoma. JAMA. 1978;240:2752\u20133.","journal-title":"JAMA"},{"key":"1721_CR32","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1517\/14728222.2011.641534","volume":"15","author":"A Desiniotis","year":"2011","unstructured":"Desiniotis A, Kyprianou N. Advances in the design and synthesis of Prazosin derivatives over the last ten years. Expert Opin Ther Targets. 2011;15:1405\u201318.","journal-title":"Expert Opin Ther Targets"},{"key":"1721_CR33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.15252\/emmm.201505421","volume":"8","author":"S Assad Kahn","year":"2016","unstructured":"Assad Kahn S, Costa SL, Gholamin S, et al. The anti-hypertensive drug Prazosin inhibits glioblastoma growth via the PKCdelta-dependent Inhibition of the AKT pathway. EMBO Mol Med. 2016;8:511\u201326.","journal-title":"EMBO Mol Med"},{"key":"1721_CR34","first-page":"535","volume":"15","author":"L Perron","year":"2004","unstructured":"Perron L, Bairati I, Harel F, Meyer F. Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control. 2004;15:535\u201341.","journal-title":"Cancer Causes Control"},{"key":"1721_CR35","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1158\/1940-6207.CAPR-11-0450","volume":"5","author":"G Nkontchou","year":"2012","unstructured":"Nkontchou G, Aout M, Mahmoudi A, et al. Effect of long-term propranolol treatment on hepatocellular carcinoma incidence in patients with HCV-associated cirrhosis. Cancer Prev Res (Phila). 2012;5:1007\u201314.","journal-title":"Cancer Prev Res (Phila)"},{"key":"1721_CR36","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1200\/JCO.2010.33.5422","volume":"29","author":"TI Barron","year":"2011","unstructured":"Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol. 2011;29:2635\u201344.","journal-title":"J Clin Oncol"},{"key":"1721_CR37","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.clbc.2015.07.001","volume":"15","author":"WK Childers","year":"2015","unstructured":"Childers WK, Hollenbeak CS, Cheriyath P. Beta-blockers reduce breast cancer recurrence and breast cancer death: a meta-analysis. Clin Breast Cancer. 2015;15:426\u201331.","journal-title":"Clin Breast Cancer"},{"key":"1721_CR38","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3332\/ecancer.2015.499","volume":"9","author":"S Banavali","year":"2015","unstructured":"Banavali S, Pasquier E, Andre N. Targeted therapy with propranolol and metronomic chemotherapy combination: sustained complete response of a relapsing metastatic angiosarcoma. Ecancermedicalscience. 2015;9:499.","journal-title":"Ecancermedicalscience"},{"key":"1721_CR39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ebiom.2016.02.026","volume":"6","author":"E Pasquier","year":"2016","unstructured":"Pasquier E, Andre N, Street J, et al. Effective management of advanced angiosarcoma by the synergistic combination of propranolol and vinblastine-based metronomic chemotherapy: a bench to bedside study. EBioMedicine. 2016;6:87\u201395.","journal-title":"EBioMedicine"},{"key":"1721_CR40","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1001\/jamadermatol.2015.2554","volume":"151","author":"W Chow","year":"2015","unstructured":"Chow W, Amaya CN, Rains S, Chow M, Dickerson EB, Bryan BA. Growth attenuation of cutaneous angiosarcoma with propranolol-mediated beta-blockade. JAMA Dermatol. 2015;151:1226\u20139.","journal-title":"JAMA Dermatol"},{"key":"1721_CR41","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s11094-005-0097-9","volume":"39","author":"AM Popov","year":"2005","unstructured":"Popov AM, Davidovich RL, Li IA, Skul\u2019beda AV, Hu SZ. Cytotoxic and antitumor activity of Antimony(III) nitrilotriacetate complexes M2SB(Nta)(HNta) \u00b7 nH2O (M\u2009=\u2009NH4, Na; n\u2009=\u20091, 2). Pharm Chem J. 2005;39:119\u201321.","journal-title":"Pharm Chem J"},{"key":"1721_CR42","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1023\/A:1007069601569","volume":"25","author":"MTH Tarafder","year":"2000","unstructured":"Tarafder MTH, Ali AM, Elias MS, Crouse KA, Silong S. Coordination chemistry and biological activity of bidentate and quadridentate nitrogen\u2013sulfur donor ligands and their complexes. Transition Met Chem. 2000;25:706\u201310.","journal-title":"Transition Met Chem"},{"key":"1721_CR43","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1016\/j.ica.2004.06.028","volume":"358","author":"SK Hadjikakou","year":"2005","unstructured":"Hadjikakou SK, Antoniadis CD, Hadjiliadis N, et al. Synthesis and characterization of new water stable antimony(III) complex with pyrimidine-2-thione and in vitro biological study. Inorg Chim Acta. 2005;358:2861\u20136.","journal-title":"Inorg Chim Acta"},{"key":"1721_CR44","doi-asserted-by":"publisher","first-page":"8652","DOI":"10.1021\/ic700756e","volume":"46","author":"II Ozturk","year":"2007","unstructured":"Ozturk II, Hadjikakou SK, Hadjiliadis N, et al. Synthesis, structural characterization, and biological studies of new antimony(III) complexes with thiones. The influence of the solvent on the geometry of the complexes. Inorg Chem. 2007;46:8652\u201361.","journal-title":"Inorg Chem"},{"key":"1721_CR45","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0020-1693(94)04391-8","volume":"232","author":"S-Z Hu","year":"1995","unstructured":"Hu S-Z, Tu L-D, Huang Y-Q, Li Z-X. Studies on the antitumor antimony(III) aminopolycarboxylic acid chelates. Crystal structures of M[Sb(pdta)] \u00b7 H2O (M\u2009=\u2009Na+, NH4+; pdta\u2009=\u2009propylenediaminetetraacetic acid). Inorg Chim Acta. 1995;232:161\u20135.","journal-title":"Inorg Chim Acta"},{"key":"1721_CR46","doi-asserted-by":"crossref","unstructured":"Sheng-Zhi H, Fu Y-M, Xu B, Tang W-D, Yu W-J. Studies, on the antitumor antimony(III) Triaminocarboxylic complexonates. Crystal structures of NH4[Sb(Hdtpa)]\u00b7H2O and Na[Sb(Hdtpa)]\u00b741\/2 H2O (dtpa\u2009=\u2009Diethylenetriaminepentaacetic Acid). Main Group Met Chem. 1997;20:169\u201380.","DOI":"10.1515\/MGMC.1997.20.3.169"},{"key":"1721_CR47","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bcp.2005.10.043","volume":"71","author":"S Wyllie","year":"2006","unstructured":"Wyllie S, Fairlamb AH. Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line. Biochem Pharmacol. 2006;71:257\u201367.","journal-title":"Biochem Pharmacol"},{"key":"1721_CR48","doi-asserted-by":"crossref","unstructured":"Tang Y, Song H, Wang Z et al. Repurposing antiparasitic antimonials to noncovalently rescue temperature-sensitive p53 mutations. Cell Rep. 2022;39.","DOI":"10.1016\/j.celrep.2022.110622"},{"key":"1721_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/bjc.1982.5","volume":"45","author":"RT Dorr","year":"1982","unstructured":"Dorr RT, Alberts DS. Cimetidine enhancement of cyclophosphamide antitumour activity. Br J Cancer. 1982;45:35\u201343.","journal-title":"Br J Cancer"},{"key":"1721_CR50","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/sj.bjc.6600048","volume":"86","author":"S Matsumoto","year":"2002","unstructured":"Matsumoto S, Imaeda Y, Umemoto S, Kobayashi K, Suzuki H, Okamoto T. Cimetidine increases survival of colorectal cancer patients with high levels of Sialyl Lewis-X and Sialyl Lewis-A epitope expression on tumour cells. Br J Cancer. 2002;86:161\u20137.","journal-title":"Br J Cancer"},{"key":"1721_CR51","doi-asserted-by":"crossref","unstructured":"Deva S, Jameson M. Histamine type 2 receptor antagonists as adjuvant treatment for resected colorectal cancer. Cochrane Database Syst Rev. 2012:CD007814.","DOI":"10.1002\/14651858.CD007814.pub2"},{"key":"1721_CR52","first-page":"53","volume":"76","author":"RD Thornes","year":"1983","unstructured":"Thornes RD, Lynch G, Sheehan MV. Coumarin and cimetidine in malignant melanoma. Ir Med J. 1983;76:53.","journal-title":"Ir Med J"},{"key":"1721_CR53","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJM198210213071716","volume":"307","author":"S Borgstrom","year":"1982","unstructured":"Borgstrom S, von Eyben FE, Flodgren P, Axelsson B, Sjogren HO. Human leukocyte interferon and cimetidine for metastatic melanoma. N Engl J Med. 1982;307:1080\u20131.","journal-title":"N Engl J Med"},{"key":"1721_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1349-7006.2010.01756.x","volume":"102","author":"M Tatokoro","year":"2011","unstructured":"Tatokoro M, Fujii Y, Kawakami S, et al. Phase-II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 2011;102:137\u201343.","journal-title":"Cancer Sci"},{"key":"1721_CR55","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-013-0585-9","volume":"30","author":"S Breuer","year":"2013","unstructured":"Breuer S, Maimon O, Appelbaum L, Peretz T, Hubert A. TL-118-anti-angiogenic treatment in pancreatic cancer: a case report. Med Oncol. 2013;30:585.","journal-title":"Med Oncol"},{"key":"1721_CR56","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/pros.2990170203","volume":"17","author":"ME Marshall","year":"1990","unstructured":"Marshall ME, Butler K, Hermansen D. Treatment of hormone-refractory stage D carcinoma of prostate with coumarin (1,2-benzopyrone) and cimetidine: a pilot study. Prostate. 1990;17:95\u20139.","journal-title":"Prostate"},{"key":"1721_CR57","first-page":"119","volume":"1","author":"K Niwa","year":"2008","unstructured":"Niwa K, Onogi K, Wu Y, Mori H, Inoue Y, Tamaya T. Prognostic implications of cimetidine on advanced serous ovarian carcinoma related to cyclooxygenase-2 expression. Mol Med Rep. 2008;1:119\u201322.","journal-title":"Mol Med Rep"},{"key":"1721_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/jnci\/83.2.139-a","volume":"83","author":"TJ Smith","year":"1991","unstructured":"Smith TJ, Kaplowitz LG. Pilot study of cimetidine in the treatment of Kaposi\u2019s sarcoma in patients with acquired immunodeficiency syndrome. J Natl Cancer Inst. 1991;83:139\u201341.","journal-title":"J Natl Cancer Inst"},{"key":"1721_CR59","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1158\/0008-5472.CAN-06-1500","volume":"66","author":"M Zakikhani","year":"2006","unstructured":"Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269\u201373.","journal-title":"Cancer Res"},{"key":"1721_CR60","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1038\/s41586-018-0350-5","volume":"559","author":"D Wu","year":"2018","unstructured":"Wu D, Hu D, Chen H, et al. Glucose-regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 2018;559:637\u201341.","journal-title":"Nature"},{"key":"1721_CR61","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.cmet.2016.12.009","volume":"25","author":"JJ Howell","year":"2017","unstructured":"Howell JJ, Hellberg K, Turner M, et al. Metformin inhibits hepatic mTORC1 signaling via dose-dependent mechanisms involving AMPK and the TSC complex. Cell Metab. 2017;25:463\u201371.","journal-title":"Cell Metab"},{"key":"1721_CR62","doi-asserted-by":"publisher","first-page":"e323","DOI":"10.1016\/j.clgc.2018.12.009","volume":"17","author":"M Mark","year":"2019","unstructured":"Mark M, Klingbiel D, Mey U, et al. Impact of addition of Metformin to abiraterone in metastatic Castration-Resistant prostate cancer patients with disease progressing while receiving abiraterone treatment (MetAb-Pro): phase 2 pilot study. Clin Genitourin Cancer. 2019;17:e323\u20138.","journal-title":"Clin Genitourin Cancer"},{"key":"1721_CR63","doi-asserted-by":"publisher","first-page":"733","DOI":"10.31557\/APJCP.2020.21.3.733","volume":"21","author":"K Petchsila","year":"2020","unstructured":"Petchsila K, Prueksaritanond N, Insin P, Yanaranop M, Chotikawichean N. Effect of metformin for decreasing proliferative marker in women with endometrial cancer: a randomized double-blind placebo-controlled trial. Asian Pac J Cancer Prev. 2020;21:733\u201341.","journal-title":"Asian Pac J Cancer Prev"},{"key":"1721_CR64","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1007\/s00432-016-2178-4","volume":"142","author":"A Bhaw-Luximon","year":"2016","unstructured":"Bhaw-Luximon A, Jhurry D. Metformin in pancreatic cancer treatment: from clinical trials through basic research to biomarker quantification. J Cancer Res Clin Oncol. 2016;142:2159\u201371.","journal-title":"J Cancer Res Clin Oncol"},{"key":"1721_CR65","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.phrs.2019.01.036","volume":"141","author":"Z-J Zhang","year":"2019","unstructured":"Zhang Z-J, Yuan J, Bi Y, Wang C, Liu Y. The effect of Metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials. Pharmacol Res. 2019;141:551\u20135.","journal-title":"Pharmacol Res"},{"key":"1721_CR66","doi-asserted-by":"publisher","first-page":"533","DOI":"10.3109\/10428199709055590","volume":"24","author":"A Newman","year":"1997","unstructured":"Newman A, Clutterbuck RD, Powles RL, Catovsky D, Millar JL. A comparison of the effect of the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors simvastatin, lovastatin and pravastatin on leukaemic and normal bone marrow progenitors. Leuk Lymphoma. 1997;24:533\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1721_CR67","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1182\/blood.V93.4.1308","volume":"93","author":"J Dimitroulakos","year":"1999","unstructured":"Dimitroulakos J, Nohynek D, Backway KL, et al. Increased sensitivity of acute myeloid leukemias to lovastatin-induced apoptosis: a potential therapeutic approach. Blood. 1999;93:1308\u201318.","journal-title":"Blood"},{"key":"1721_CR68","first-page":"2067","volume":"7","author":"WW Wong","year":"2001","unstructured":"Wong WW, Tan MM, Xia Z, Dimitroulakos J, Minden MD, Penn LZ. Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. Clin Cancer Res. 2001;7:2067\u201375.","journal-title":"Clin Cancer Res"},{"key":"1721_CR69","doi-asserted-by":"publisher","first-page":"4787","DOI":"10.1182\/blood-2009-07-230508","volume":"115","author":"JW Clendening","year":"2010","unstructured":"Clendening JW, Pandyra A, Li Z, et al. Exploiting the mevalonate pathway to distinguish statin-sensitive multiple myeloma. Blood. 2010;115:4787\u201397.","journal-title":"Blood"},{"key":"1721_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/srep44841","volume":"7","author":"J Alizadeh","year":"2017","unstructured":"Alizadeh J, Zeki AA, Mirzaei N, et al. Mevalonate cascade inhibition by Simvastatin induces the intrinsic apoptosis pathway via depletion of isoprenoids in tumor cells. Sci Rep. 2017;7:44841.","journal-title":"Sci Rep"},{"key":"1721_CR71","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s10549-009-0507-x","volume":"119","author":"ER Garwood","year":"2010","unstructured":"Garwood ER, Kumar AS, Baehner FL, et al. Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer. Breast Cancer Res Treat. 2010;119:137\u201344.","journal-title":"Breast Cancer Res Treat"},{"key":"1721_CR72","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41391-020-0221-7","volume":"23","author":"J Longo","year":"2020","unstructured":"Longo J, Hamilton RJ, Masoomian M, et al. A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer Prostatic Dis. 2020;23:630\u20137.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1721_CR73","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00223-004-0024-1","volume":"75","author":"MJ Rogers","year":"2004","unstructured":"Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int. 2004;75:451\u201361.","journal-title":"Calcif Tissue Int"},{"key":"1721_CR74","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","volume":"3","author":"J Zekri","year":"2014","unstructured":"Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol. 2014;3:25\u201335.","journal-title":"J Bone Oncol"},{"key":"1721_CR75","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1089\/jir.2005.25.144","volume":"25","author":"B Vincenzi","year":"2005","unstructured":"Vincenzi B, Santini D, Dicuonzo G, et al. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005;25:144\u201351.","journal-title":"J Interferon Cytokine Res"},{"key":"1721_CR76","first-page":"1351","volume":"15","author":"D Santini","year":"2006","unstructured":"Santini D, Vincenzi B, Hannon RA, et al. Changes in bone resorption and vascular endothelial growth factor after a single Zoledronic acid infusion in cancer patients with bone metastases from solid tumours. Oncol Rep. 2006;15:1351\u20137.","journal-title":"Oncol Rep"},{"key":"1721_CR77","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1365-2249.2010.04167.x","volume":"161","author":"S Meraviglia","year":"2010","unstructured":"Meraviglia S, Eberl M, Vermijlen D, et al. In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin Exp Immunol. 2010;161:290\u20137.","journal-title":"Clin Exp Immunol"},{"key":"1721_CR78","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","volume":"9","author":"M Gnant","year":"2008","unstructured":"Gnant M, Mlineritsch B, Luschin-Ebengreuth G, et al. Adjuvant endocrine therapy plus Zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy. Lancet Oncol. 2008;9:840\u20139.","journal-title":"Lancet Oncol"},{"key":"1721_CR79","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1634\/theoncologist.2007-0206","volume":"13","author":"A Brufsky","year":"2008","unstructured":"Brufsky A, Bundred N, Coleman R, et al. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist. 2008;13:503\u201314.","journal-title":"Oncologist"},{"key":"1721_CR80","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","volume":"21","author":"H Eidtmann","year":"2010","unstructured":"Eidtmann H, de Boer R, Bundred N, et al. Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study. Ann Oncol. 2010;21:2188\u201394.","journal-title":"Ann Oncol"},{"key":"1721_CR81","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000007256","volume":"46","author":"K Hamada","year":"2000","unstructured":"Hamada K, Mikasa K, Yunou Y, et al. Adjuvant effect of clarithromycin on chemotherapy for murine lung cancer. Chemotherapy. 2000;46:49\u201361.","journal-title":"Chemotherapy"},{"key":"1721_CR82","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1023\/A:1006605725619","volume":"17","author":"J Yatsunami","year":"1999","unstructured":"Yatsunami J, Fukuno Y, Nagata M, et al. Antiangiogenic and antitumor effects of 14-membered ring macrolides on mouse B16 melanoma cells. Clin Exp Metastasis. 1999;17:361\u20137.","journal-title":"Clin Exp Metastasis"},{"key":"1721_CR83","first-page":"815","volume":"37","author":"M Nakamura","year":"2010","unstructured":"Nakamura M, Kikukawa Y, Takeya M, Mitsuya H, Hata H. Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol. 2010;37:815\u201320.","journal-title":"Int J Oncol"},{"key":"1721_CR84","first-page":"579","volume":"90","author":"B Durie","year":"1997","unstructured":"Durie B. Clarithromycin (Biaxin) as primary treatment for myeloma. Blood. 1997;90:579.","journal-title":"Blood"},{"key":"1721_CR85","first-page":"658","volume":"87","author":"P Musto","year":"2002","unstructured":"Musto P, Falcone A, Sanpaolo G, Bodenizza C, Carotenuto M, Carella AM. Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report. Haematologica. 2002;87:658\u20139.","journal-title":"Haematologica"},{"key":"1721_CR86","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1385\/MO:18:1:79","volume":"18","author":"TC Morris","year":"2001","unstructured":"Morris TC, Ranaghan L, Morrison J. Northern Ireland regional haematology G. phase II trial of clarithromycin and pamidronate therapy in myeloma. Med Oncol. 2001;18:79\u201384.","journal-title":"Med Oncol"},{"key":"1721_CR87","doi-asserted-by":"publisher","first-page":"4441","DOI":"10.1182\/blood.V93.12.4441","volume":"93","author":"AK Stewart","year":"1999","unstructured":"Stewart AK, Trudel S, Al-Berouti BM, Sutton DM, Meharchand J. Lack of response to short-term use of clarithromycin (BIAXIN) in multiple myeloma. Blood. 1999;93:4441.","journal-title":"Blood"},{"key":"1721_CR88","unstructured":"Vescio R. American society of hematology meeting. Blood 2001;98."},{"key":"1721_CR89","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1080\/1042819021000006303","volume":"43","author":"M Coleman","year":"2002","unstructured":"Coleman M, Leonard J, Lyons L, et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom\u2019s macroglobulinemia. Leuk Lymphoma. 2002;43:1777\u201382.","journal-title":"Leuk Lymphoma"},{"key":"1721_CR90","doi-asserted-by":"crossref","first-page":"237a","DOI":"10.1182\/blood-2002-09-2725","volume":"102","author":"R Niesvizky","year":"2003","unstructured":"Niesvizky R. Dexamethasone alone, or in combination with low-dose thalidomide as induction therapy for advanced multiple myeloma, and the effect of the addition of clarithromycin (Biaxin^< TM>) on response rate. Interim results of a prospective, sequential, randomized trial. Blood. 2003;102:237a.","journal-title":"Blood"},{"key":"1721_CR91","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3109\/10428194.2012.656105","volume":"53","author":"AM Carella","year":"2012","unstructured":"Carella AM, Beltrami G, Pica G, Carella A, Catania G. Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma. 2012;53:1409\u201311.","journal-title":"Leuk Lymphoma"},{"key":"1721_CR92","doi-asserted-by":"publisher","first-page":"203","DOI":"10.5045\/kjh.2011.46.3.203","volume":"46","author":"M Ohe","year":"2011","unstructured":"Ohe M, Hashino S. A case of follicular B-cell lymphoma treated using clarithromycin. Korean J Hematol. 2011;46:203\u20136.","journal-title":"Korean J Hematol"},{"key":"1721_CR93","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2017.96","volume":"7","author":"Y Kusano","year":"2017","unstructured":"Kusano Y, Yokoyama M, Terui Y, et al. High pretreatment level of soluble interleukin-2 receptor is a robust prognostic factor in patients with follicular lymphoma treated with R-CHOP-like therapy. Blood Cancer J. 2017;7:e614.","journal-title":"Blood Cancer J"},{"key":"1721_CR94","doi-asserted-by":"publisher","first-page":"293","DOI":"10.5045\/kjh.2012.47.4.293","volume":"47","author":"M Ohe","year":"2012","unstructured":"Ohe M, Hashino S, Hattori A. Successful treatment of diffuse large B-cell lymphoma with clarithromycin and prednisolone. Korean J Hematol. 2012;47:293\u20137.","journal-title":"Korean J Hematol"},{"key":"1721_CR95","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1159\/000239580","volume":"43","author":"K Mikasa","year":"1997","unstructured":"Mikasa K, Sawaki M, Kita E, et al. Significant survival benefit to patients with advanced non-small-cell lung cancer from treatment with clarithromycin. Chemotherapy. 1997;43:288\u201396.","journal-title":"Chemotherapy"},{"key":"1721_CR96","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3892\/ol.2017.6325","volume":"14","author":"H Tsubamoto","year":"2017","unstructured":"Tsubamoto H, Ueda T, Inoue K, Sakata K, Shibahara H, Sonoda T. Repurposing itraconazole as an anticancer agent. Oncol Lett. 2017;14:1240\u20136.","journal-title":"Oncol Lett"},{"key":"1721_CR97","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.3892\/ol.2017.6569","volume":"14","author":"R Pounds","year":"2017","unstructured":"Pounds R, Leonard S, Dawson C, Kehoe S. Repurposing itraconazole for the treatment of cancer. Oncol Lett. 2017;14:2587\u201397.","journal-title":"Oncol Lett"},{"key":"1721_CR98","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1021\/cb600362d","volume":"2","author":"CR Chong","year":"2007","unstructured":"Chong CR, Xu J, Lu J, Bhat S, Sullivan DJ Jr., Liu JO. Inhibition of angiogenesis by the antifungal drug itraconazole. ACS Chem Biol. 2007;2:263\u201370.","journal-title":"ACS Chem Biol"},{"key":"1721_CR99","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jid.2018.12.028","volume":"139","author":"S Chen","year":"2019","unstructured":"Chen S, Zhuang K, Sun K, et al. Itraconazole induces regression of infantile hemangioma via downregulation of the Platelet-Derived growth Factor-D\/PI3K\/Akt\/mTOR pathway. J Invest Dermatol. 2019;139:1574\u201382.","journal-title":"J Invest Dermatol"},{"key":"1721_CR100","first-page":"2481","volume":"34","author":"H Tsubamoto","year":"2014","unstructured":"Tsubamoto H, Sonoda T, Yamasaki M, Inoue K. Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer. Anticancer Res. 2014;34:2481\u20137.","journal-title":"Anticancer Res"},{"key":"1721_CR101","first-page":"4191","volume":"35","author":"H Tsubamoto","year":"2015","unstructured":"Tsubamoto H, Sonoda T, Ikuta S, Tani S, Inoue K, Yamanaka N. Combination chemotherapy with itraconazole for treating metastatic pancreatic cancer in the second-line or additional setting. Anticancer Res. 2015;35:4191\u20136.","journal-title":"Anticancer Res"},{"key":"1721_CR102","first-page":"3839","volume":"34","author":"H Tsubamoto","year":"2014","unstructured":"Tsubamoto H, Sonoda T, Inoue K. Impact of itraconazole on the survival of heavily pre-treated patients with triple-negative breast cancer. Anticancer Res. 2014;34:3839\u201344.","journal-title":"Anticancer Res"},{"key":"1721_CR103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105886","volume":"55","author":"MS Copley","year":"2020","unstructured":"Copley MS, Waldron M, Athans V, et al. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: a retrospective study. Int J Antimicrob Agents. 2020;55:105886.","journal-title":"Int J Antimicrob Agents"},{"key":"1721_CR104","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1097\/JTO.0b013e31828c3950","volume":"8","author":"CM Rudin","year":"2013","unstructured":"Rudin CM, Brahmer JR, Juergens RA, et al. Phase 2 study of pemetrexed and Itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2013;8:619\u201323.","journal-title":"J Thorac Oncol"},{"key":"1721_CR105","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1158\/1535-7163.MCT-21-0801","volume":"22","author":"K Zhou","year":"2023","unstructured":"Zhou K, Cheong JE, Krishnaji ST, et al. Inhibition of wnt signaling in colon cancer cells via an oral drug that facilitates TNIK degradation. Mol Cancer Ther. 2023;22:25\u201336.","journal-title":"Mol Cancer Ther"},{"key":"1721_CR106","first-page":"2963","volume":"8","author":"T Mukhopadhyay","year":"2002","unstructured":"Mukhopadhyay T, Sasaki J, Ramesh R, Roth JA. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2002;8:2963\u20139.","journal-title":"Clin Cancer Res"},{"key":"1721_CR107","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/neuonc\/nor077","volume":"13","author":"RY Bai","year":"2011","unstructured":"Bai RY, Staedtke V, Aprhys CM, Gallia GL, Riggins GJ. Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme. Neuro Oncol. 2011;13:974\u201382.","journal-title":"Neuro Oncol"},{"key":"1721_CR108","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1158\/1541-7786.MCR-07-2159","volume":"6","author":"N Doudican","year":"2008","unstructured":"Doudican N, Rodriguez A, Osman I, Orlow SJ. Mebendazole induces apoptosis via Bcl-2 inactivation in chemoresistant melanoma cells. Mol Cancer Res. 2008;6:1308\u201315.","journal-title":"Mol Cancer Res"},{"key":"1721_CR109","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.4158\/EP10390.CR","volume":"17","author":"IY Dobrosotskaya","year":"2011","unstructured":"Dobrosotskaya IY, Hammer GD, Schteingart DE, Maturen KE, Worden FP. Mebendazole monotherapy and long-term disease control in metastatic adrenocortical carcinoma. Endocr Pract. 2011;17:e59\u201362.","journal-title":"Endocr Pract"},{"key":"1721_CR110","doi-asserted-by":"publisher","first-page":"427","DOI":"10.3109\/0284186X.2013.844359","volume":"53","author":"P Nygren","year":"2014","unstructured":"Nygren P, Larsson R. Drug repositioning from bench to bedside: tumour remission by the antihelmintic drug Mebendazole in refractory metastatic colon cancer. Acta Oncol. 2014;53:427\u20138.","journal-title":"Acta Oncol"},{"key":"1721_CR111","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdaa154","volume":"3","author":"GL Gallia","year":"2021","unstructured":"Gallia GL, Holdhoff M, Brem H, et al. Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial. Neuro-Oncol Adv. 2021;3:vdaa154.","journal-title":"Neuro-Oncol Adv"},{"key":"1721_CR112","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1089\/hum.1996.7.4-515","volume":"7","author":"JA Eastham","year":"1996","unstructured":"Eastham JA, Chen SH, Sehgal I, et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum Gene Ther. 1996;7:515\u201323.","journal-title":"Hum Gene Ther"},{"key":"1721_CR113","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1016\/j.ymthe.2005.11.022","volume":"13","author":"G Ayala","year":"2006","unstructured":"Ayala G, Satoh T, Li R, et al. Biological response determinants in HSV-tk\u2009+\u2009ganciclovir gene therapy for prostate cancer. Mol Ther. 2006;13:716\u201328.","journal-title":"Mol Ther"},{"key":"1721_CR114","doi-asserted-by":"publisher","first-page":"4336","DOI":"10.1016\/j.biomaterials.2012.02.058","volume":"33","author":"D Shao","year":"2012","unstructured":"Shao D, Zeng Q, Fan Z, et al. Monitoring HSV-TK\/ganciclovir cancer suicide gene therapy using CdTe\/CdS core\/shell quantum dots. Biomaterials. 2012;33:4336\u201344.","journal-title":"Biomaterials"},{"key":"1721_CR115","first-page":"943","volume":"24","author":"AM Maatta","year":"2004","unstructured":"Maatta AM, Tenhunen A, Pasanen T, et al. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy. Int J Oncol. 2004;24:943\u20139.","journal-title":"Int J Oncol"},{"key":"1721_CR116","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s10637-019-00733-3","volume":"37","author":"S Paskas","year":"2019","unstructured":"Paskas S, Mazzon E, Basile MS, et al. Lopinavir-NO, a nitric oxide-releasing HIV protease inhibitor, suppresses the growth of melanoma cells in vitro and in vivo. Invest New Drugs. 2019;37:1014\u201328.","journal-title":"Invest New Drugs"},{"key":"1721_CR117","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.21873\/anticanres.13793","volume":"39","author":"K Okubo","year":"2019","unstructured":"Okubo K, Isono M, Asano T, Sato A. Lopinavir-ritonavir combination induces Endoplasmic reticulum stress and kills urological cancer cells. Anticancer Res. 2019;39:5891\u2013901.","journal-title":"Anticancer Res"},{"key":"1721_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.01693","volume":"10","author":"R Marima","year":"2020","unstructured":"Marima R, Hull R, Dlamini Z, Penny C. Efavirenz and lopinavir\/ritonavir alter cell cycle regulation in lung cancer. Front Oncol. 2020;10:1693.","journal-title":"Front Oncol"},{"key":"1721_CR119","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/sj.bjc.6605756","volume":"103","author":"S Franceschi","year":"2010","unstructured":"Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV cohort study. Br J Cancer. 2010;103:416\u201322.","journal-title":"Br J Cancer"},{"key":"1721_CR120","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/sj.bjc.6604520","volume":"99","author":"S Franceschi","year":"2008","unstructured":"Franceschi S, Maso LD, Rickenbach M, et al. Kaposi sarcoma incidence in the Swiss HIV cohort study before and after highly active antiretroviral therapy. Br J Cancer. 2008;99:800\u20134.","journal-title":"Br J Cancer"},{"key":"1721_CR121","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1470-2045(08)70334-6","volume":"10","author":"WA Chow","year":"2009","unstructured":"Chow WA, Jiang C, Guan M. Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol. 2009;10:61\u201371.","journal-title":"Lancet Oncol"},{"key":"1721_CR122","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-8-26","volume":"8","author":"S Kumar","year":"2009","unstructured":"Kumar S, Bryant CS, Chamala S, et al. Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells. Mol Cancer. 2009;8:26.","journal-title":"Mol Cancer"},{"key":"1721_CR123","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3390\/ph7010046","volume":"7","author":"RB Batchu","year":"2014","unstructured":"Batchu RB, Gruzdyn OV, Bryant CS, et al. Ritonavir-mediated induction of apoptosis in pancreatic cancer occurs via the RB\/E2F-1 and AKT pathways. Pharmaceuticals. 2014;7:46\u201357.","journal-title":"Pharmaceuticals"},{"key":"1721_CR124","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.bbrc.2019.01.117","volume":"510","author":"J Jin","year":"2019","unstructured":"Jin J, Xiang W, Wu S, Wang M, Xiao M, Deng A. Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer. Biochem Biophys Res Commun. 2019;510:580\u20136.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR125","doi-asserted-by":"publisher","first-page":"2241","DOI":"10.1038\/s41388-018-0567-7","volume":"38","author":"KA Urtishak","year":"2019","unstructured":"Urtishak KA, Wang LS, Culjkovic-Kraljacic B, et al. Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia. Oncogene. 2019;38:2241\u201362.","journal-title":"Oncogene"},{"key":"1721_CR126","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1158\/1078-0432.CCR-10-2334","volume":"17","author":"F Pettersson","year":"2011","unstructured":"Pettersson F, Yau C, Dobocan MC, et al. Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer. Clin Cancer Res. 2011;17:2874\u201384.","journal-title":"Clin Cancer Res"},{"key":"1721_CR127","doi-asserted-by":"publisher","first-page":"3037","DOI":"10.1038\/onc.2016.457","volume":"36","author":"F Volpin","year":"2017","unstructured":"Volpin F, Casaos J, Sesen J, et al. Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic. Oncogene. 2017;36:3037\u201347.","journal-title":"Oncogene"},{"key":"1721_CR128","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.bbrc.2008.07.163","volume":"375","author":"K Tan","year":"2008","unstructured":"Tan K, Culjkovic B, Amri A, Borden KL. Ribavirin targets eIF4E dependent Akt survival signaling. Biochem Biophys Res Commun. 2008;375:341\u20135.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR129","doi-asserted-by":"crossref","unstructured":"Tan J, Ye J, Song M, Zhou M, Hu Y. Ribavirin augments doxorubicin\u2019s efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018;32.","DOI":"10.1002\/jbt.22007"},{"key":"1721_CR130","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.bbrc.2016.12.025","volume":"482","author":"D Dai","year":"2017","unstructured":"Dai D, Chen H, Tang J, Tang Y. Inhibition of mTOR\/eIF4E by anti-viral drug ribavirin effectively enhances the effects of Paclitaxel in oral tongue squamous cell carcinoma. Biochem Biophys Res Commun. 2017;482:1259\u201364.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR131","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.bbrc.2018.10.124","volume":"506","author":"J Chen","year":"2018","unstructured":"Chen J, Xu X, Chen J. Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. Biochem Biophys Res Commun. 2018;506:604\u201310.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR132","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1158\/1535-7163.MCT-19-0572","volume":"19","author":"S Huq","year":"2020","unstructured":"Huq S, Casaos J, Serra R, et al. Repurposing the FDA-approved antiviral drug ribavirin as targeted therapy for nasopharyngeal carcinoma. Mol Cancer Ther. 2020;19:1797\u2013808.","journal-title":"Mol Cancer Ther"},{"key":"1721_CR133","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.1158\/0008-5472.CAN-07-2970","volume":"68","author":"PC Li","year":"2008","unstructured":"Li PC, Lam E, Roos WP, Zdzienicka MZ, Kaina B, Efferth T. Artesunate derived from traditional Chinese medicine induces DNA damage and repair. Cancer Res. 2008;68:4347\u201351.","journal-title":"Cancer Res"},{"key":"1721_CR134","doi-asserted-by":"publisher","first-page":"4461","DOI":"10.3892\/mmr.2016.5073","volume":"13","author":"J Jia","year":"2016","unstructured":"Jia J, Qin Y, Zhang L, et al. Artemisinin inhibits gallbladder cancer cell lines through triggering cell cycle arrest and apoptosis. Mol Med Rep. 2016;13:4461\u20138.","journal-title":"Mol Med Rep"},{"key":"1721_CR135","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.yexmp.2019.01.006","volume":"107","author":"AL Greenshields","year":"2019","unstructured":"Greenshields AL, Fernando W, Hoskin DW. The anti-malarial drug Artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells. Exp Mol Pathol. 2019;107:10\u201322.","journal-title":"Exp Mol Pathol"},{"key":"1721_CR136","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1007\/s10637-011-9676-7","volume":"30","author":"CM Cabello","year":"2012","unstructured":"Cabello CM, Lamore SD, Bair WB, et al. The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest New Drugs. 2012;30:1289\u2013301.","journal-title":"Invest New Drugs"},{"key":"1721_CR137","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1002\/ddr.21590","volume":"80","author":"VL Kumar","year":"2019","unstructured":"Kumar VL, Verma S, Das P. Artesunate suppresses inflammation and oxidative stress in a rat model of colorectal cancer. Drug Dev Res. 2019;80:1089\u201397.","journal-title":"Drug Dev Res"},{"key":"1721_CR138","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.radonc.2013.06.033","volume":"108","author":"B Jutten","year":"2013","unstructured":"Jutten B, Keulers TG, Schaaf MB, et al. EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival. Radiother Oncol. 2013;108:479\u201383.","journal-title":"Radiother Oncol"},{"key":"1721_CR139","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.canlet.2013.07.021","volume":"339","author":"YJ Song","year":"2013","unstructured":"Song YJ, Zhang SS, Guo XL, et al. Autophagy contributes to the survival of CD133\u2009+\u2009liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment. Cancer Lett. 2013;339:70\u201381.","journal-title":"Cancer Lett"},{"key":"1721_CR140","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3892\/or.2015.4380","volume":"35","author":"T Hu","year":"2016","unstructured":"Hu T, Li P, Luo Z, et al. Chloroquine inhibits hepatocellular carcinoma cell growth in vitro and in vivo. Oncol Rep. 2016;35:43\u20139.","journal-title":"Oncol Rep"},{"key":"1721_CR141","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.4161\/auto.29119","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala R, Chang YC, Hu J, et al. Combined MTOR and autophagy inhibition: phase i trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy. 2014;10:1391\u2013402.","journal-title":"Autophagy"},{"key":"1721_CR142","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.4161\/auto.29118","volume":"10","author":"R Rangwala","year":"2014","unstructured":"Rangwala R, Leone R, Chang YC, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy. 2014;10:1369\u201379.","journal-title":"Autophagy"},{"key":"1721_CR143","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.4161\/auto.29231","volume":"10","author":"D Mahalingam","year":"2014","unstructured":"Mahalingam D, Mita M, Sarantopoulos J, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor Vorinostat in patients with advanced solid tumors. Autophagy. 2014;10:1403\u201314.","journal-title":"Autophagy"},{"key":"1721_CR144","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1097\/JTO.0b013e318262de4a","volume":"7","author":"SB Goldberg","year":"2012","unstructured":"Goldberg SB, Supko JG, Neal JW, et al. A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer. J Thorac Oncol. 2012;7:1602\u20138.","journal-title":"J Thorac Oncol"},{"key":"1721_CR145","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.4161\/auto.29264","volume":"10","author":"DT Vogl","year":"2014","unstructured":"Vogl DT, Stadtmauer EA, Tan KS, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed\/refractory myeloma. Autophagy. 2014;10:1380\u201390.","journal-title":"Autophagy"},{"key":"1721_CR146","doi-asserted-by":"publisher","first-page":"4402","DOI":"10.1245\/s10434-015-4566-4","volume":"22","author":"BA Boone","year":"2015","unstructured":"Boone BA, Bahary N, Zureikat AH, et al. Safety and biologic response of pre-operative autophagy inhibition in combination with gemcitabine in patients with pancreatic adenocarcinoma. Ann Surg Oncol. 2015;22:4402\u201310.","journal-title":"Ann Surg Oncol"},{"key":"1721_CR147","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1634\/theoncologist.2014-0086","volume":"19","author":"BM Wolpin","year":"2014","unstructured":"Wolpin BM, Rubinson DA, Wang X, et al. Phase II and pharmacodynamic study of autophagy inhibition using hydroxychloroquine in patients with metastatic pancreatic adenocarcinoma. Oncologist. 2014;19:637\u20138.","journal-title":"Oncologist"},{"key":"1721_CR148","doi-asserted-by":"publisher","first-page":"29808","DOI":"10.18632\/oncotarget.5060","volume":"6","author":"MS Chi","year":"2015","unstructured":"Chi MS, Lee CY, Huang SC, et al. Double autophagy modulators reduce 2-deoxyglucose uptake in sarcoma patients. Oncotarget. 2015;6:29808\u201317.","journal-title":"Oncotarget"},{"key":"1721_CR149","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1097\/00001813-199609000-00005","volume":"7","author":"A Didier","year":"1996","unstructured":"Didier A, Loor F. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anticancer Drugs. 1996;7:745\u201351.","journal-title":"Anticancer Drugs"},{"key":"1721_CR150","doi-asserted-by":"publisher","DOI":"10.1111\/cpr.12543","volume":"52","author":"P Zhang","year":"2019","unstructured":"Zhang P, Zhang Y, Liu K, et al. Ivermectin induces cell cycle arrest and apoptosis of HeLa cells via mitochondrial pathway. Cell Prolif. 2019;52:e12543.","journal-title":"Cell Prolif"},{"key":"1721_CR151","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.bbrc.2017.08.097","volume":"492","author":"M Zhu","year":"2017","unstructured":"Zhu M, Li Y, Zhou Z. Antibiotic ivermectin preferentially targets renal cancer through inducing mitochondrial dysfunction and oxidative damage. Biochem Biophys Res Commun. 2017;492:373\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR152","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.bbrc.2018.02.063","volume":"497","author":"J Wang","year":"2018","unstructured":"Wang J, Xu Y, Wan H, Hu J. Antibiotic ivermectin selectively induces apoptosis in chronic myeloid leukemia through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2018;497:241\u20137.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR153","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.1158\/0008-5472.CAN-15-2887","volume":"76","author":"Q Dou","year":"2016","unstructured":"Dou Q, Chen HN, Wang K, et al. Ivermectin induces cytostatic autophagy by blocking the PAK1\/Akt axis in breast cancer. Cancer Res. 2016;76:4457\u201369.","journal-title":"Cancer Res"},{"key":"1721_CR154","doi-asserted-by":"crossref","unstructured":"Liu J, Liang H, Chen C et al. Ivermectin induces autophagy-mediated cell death through the AKT\/mTOR signaling pathway in glioma cells. Biosci Rep. 2019;39.","DOI":"10.1042\/BSR20192489"},{"key":"1721_CR155","doi-asserted-by":"publisher","first-page":"107666","DOI":"10.18632\/oncotarget.22587","volume":"8","author":"S Nambara","year":"2017","unstructured":"Nambara S, Masuda T, Nishio M, et al. Antitumor effects of the antiparasitic agent ivermectin via inhibition of Yes-associated protein 1 expression in gastric cancer. Oncotarget. 2017;8:107666\u201377.","journal-title":"Oncotarget"},{"key":"1721_CR156","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.15252\/emmm.201404084","volume":"6","author":"A Melotti","year":"2014","unstructured":"Melotti A, Mas C, Kuciak M, Lorente-Trigos A, Borges I, Ruiz i Altaba A. The river blindness drug ivermectin and related macrocyclic lactones inhibit WNT-TCF pathway responses in human cancer. EMBO Mol Med. 2014;6:1263\u201378.","journal-title":"EMBO Mol Med"},{"key":"1721_CR157","doi-asserted-by":"publisher","first-page":"E71","DOI":"10.1073\/pnas.1517188113","volume":"113","author":"M Nishio","year":"2016","unstructured":"Nishio M, Sugimachi K, Goto H, et al. Dysregulated YAP1\/TAZ and TGF-beta signaling mediate hepatocarcinogenesis in Mob1a\/1b-deficient mice. Proc Natl Acad Sci USA. 2016;113:E71-80.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1721_CR158","doi-asserted-by":"publisher","first-page":"4837","DOI":"10.21873\/anticanres.13669","volume":"39","author":"K Intuyod","year":"2019","unstructured":"Intuyod K, Hahnvajanawong C, Pinlaor P, Pinlaor S. Anti-parasitic drug ivermectin exhibits potent anticancer activity against gemcitabine-resistant cholangiocarcinoma in vitro. Anticancer Res. 2019;39:4837\u201343.","journal-title":"Anticancer Res"},{"key":"1721_CR159","first-page":"243","volume":"3","author":"H Hashimoto","year":"2009","unstructured":"Hashimoto H, Messerli SM, Sudo T, Maruta H. Ivermectin inactivates the kinase PAK1 and blocks the PAK1-dependent growth of human ovarian cancer and NF2 tumor cell lines. Drug Discov Ther. 2009;3:243\u20136.","journal-title":"Drug Discov Ther"},{"key":"1721_CR160","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.bbrc.2016.10.064","volume":"480","author":"Y Liu","year":"2016","unstructured":"Liu Y, Fang S, Sun Q, Liu B. Anthelmintic drug ivermectin inhibits angiogenesis, growth and survival of glioblastoma through inducing mitochondrial dysfunction and oxidative stress. Biochem Biophys Res Commun. 2016;480:415\u201321.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR161","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.clsc.2016.05.001","volume":"1","author":"F Gallardo","year":"2016","unstructured":"Gallardo F, Teiti I, Rochaix P, et al. Macrocyclic lactones block melanoma Growth, metastases development and potentiate activity of Anti\u2013BRAF V600 inhibitors. Clin Skin Cancer. 2016;1:4\u2013e143.","journal-title":"Clin Skin Cancer"},{"key":"1721_CR162","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1182\/blood-2010-01-262675","volume":"116","author":"S Sharmeen","year":"2010","unstructured":"Sharmeen S, Skrtic M, Sukhai MA, et al. The antiparasitic agent ivermectin induces chloride-dependent membrane hyperpolarization and cell death in leukemia cells. Blood. 2010;116:3593\u2013603.","journal-title":"Blood"},{"key":"1721_CR163","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1053\/j.gastro.2017.02.039","volume":"152","author":"B Chen","year":"2017","unstructured":"Chen B, Wei W, Ma L, et al. Computational discovery of niclosamide ethanolamine, a repurposed drug candidate that reduces growth of hepatocellular carcinoma cells in vitro and in mice by inhibiting cell division cycle 37 signaling. Gastroenterology. 2017;152:2022\u201336.","journal-title":"Gastroenterology"},{"key":"1721_CR164","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1093\/jnci\/djr190","volume":"103","author":"U Sack","year":"2011","unstructured":"Sack U, Walther W, Scudiero D, et al. Novel effect of antihelminthic niclosamide on S100A4-mediated metastatic progression in colon cancer. J Natl Cancer Inst. 2011;103:1018\u201336.","journal-title":"J Natl Cancer Inst"},{"key":"1721_CR165","doi-asserted-by":"publisher","first-page":"5292","DOI":"10.1038\/s41388-018-0340-y","volume":"37","author":"L Lu","year":"2018","unstructured":"Lu L, Dong J, Wang L, et al. Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide. Oncogene. 2018;37:5292\u2013304.","journal-title":"Oncogene"},{"key":"1721_CR166","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1038\/onc.2014.277","volume":"34","author":"ML King","year":"2015","unstructured":"King ML, Lindberg ME, Stodden GR, et al. WNT7A\/beta-catenin signaling induces FGF1 and influences sensitivity to niclosamide in ovarian cancer. Oncogene. 2015;34:3452\u201362.","journal-title":"Oncogene"},{"key":"1721_CR167","doi-asserted-by":"publisher","first-page":"726","DOI":"10.2174\/1568009615666150629132157","volume":"15","author":"Z Liao","year":"2015","unstructured":"Liao Z, Nan G, Yan Z, et al. The anthelmintic drug niclosamide inhibits the proliferative activity of human osteosarcoma cells by targeting multiple signal pathways. Curr Cancer Drug Targets. 2015;15:726\u201338.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"1721_CR168","doi-asserted-by":"publisher","first-page":"178","DOI":"10.5732\/cjc.011.10290","volume":"31","author":"JX Pan","year":"2012","unstructured":"Pan JX, Ding K, Wang CY. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells. Chin J Cancer. 2012;31(4):178\u201384.","journal-title":"Chin J Cancer"},{"key":"1721_CR169","doi-asserted-by":"publisher","first-page":"34630","DOI":"10.18632\/oncotarget.8969","volume":"7","author":"RL Stewart","year":"2016","unstructured":"Stewart RL, Carpenter BL, West DS, et al. S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide. Oncotarget. 2016;7:34630\u201342.","journal-title":"Oncotarget"},{"key":"1721_CR170","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-30692-3","volume":"8","author":"LH Wang","year":"2018","unstructured":"Wang LH, Xu M, Fu LQ, Chen XY, Yang F. The antihelminthic niclosamide inhibits cancer stemness, extracellular matrix remodeling, and metastasis through dysregulation of the nuclear beta-catenin\/c-Myc axis in OSCC. Sci Rep. 2018;8:12776.","journal-title":"Sci Rep"},{"key":"1721_CR171","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/tox.22551","volume":"33","author":"MH Chien","year":"2018","unstructured":"Chien MH, Ho YC, Yang SF, et al. Niclosamide, an oral antihelmintic drug, exhibits antimetastatic activity in hepatocellular carcinoma cells through downregulating twist-mediated CD10 expression. Environ Toxicol. 2018;33:659\u201369.","journal-title":"Environ Toxicol"},{"key":"1721_CR172","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2019.08.012","volume":"169","author":"Y Zhu","year":"2019","unstructured":"Zhu Y, Zuo W, Chen L, et al. Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway. Biochem Pharmacol. 2019;169:113610.","journal-title":"Biochem Pharmacol"},{"key":"1721_CR173","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.biopha.2017.05.097","volume":"92","author":"K Yu","year":"2017","unstructured":"Yu K, Wang T, Li Y, et al. Niclosamide induces apoptosis through mitochondrial intrinsic pathway and inhibits migration and invasion in human thyroid cancer in vitro. Biomed Pharmacother. 2017;92:403\u201311.","journal-title":"Biomed Pharmacother"},{"key":"1721_CR174","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/archinte.1976.03630070063019","volume":"136","author":"HM Golomb","year":"1976","unstructured":"Golomb HM, Rowley J, Vardiman J, Baron J, Locker G, Krasnow S. Partial deletion of long arm of chromosome 17: a specific abnormality in acute promyelocytic leukemia? Arch Intern Med. 1976;136:825\u20138.","journal-title":"Arch Intern Med"},{"key":"1721_CR175","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/0002-9343(84)90994-X","volume":"76","author":"RA Larson","year":"1984","unstructured":"Larson RA, Kondo K, Vardiman JW, Butler AE, Golomb HM, Rowley JD. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia. Am J Med. 1984;76:827\u201341.","journal-title":"Am J Med"},{"key":"1721_CR176","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/blood-2007-07-102798","volume":"111","author":"ZY Wang","year":"2008","unstructured":"Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood. 2008;111:2505\u201315.","journal-title":"Blood"},{"key":"1721_CR177","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/BF00702866","volume":"80","author":"MG Mattei","year":"1988","unstructured":"Mattei MG, Petkovich M, Mattei JF, Brand N, Chambon P. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17. Hum Genet. 1988;80:186\u20138.","journal-title":"Hum Genet"},{"key":"1721_CR178","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/0092-8674(91)90113-D","volume":"66","author":"H de The","year":"1991","unstructured":"de The H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A. The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell. 1991;66:675\u201384.","journal-title":"Cell"},{"key":"1721_CR179","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/0092-8674(91)90112-C","volume":"66","author":"A Kakizuka","year":"1991","unstructured":"Kakizuka A, Miller WH Jr., Umesono K, et al. Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR alpha with a novel putative transcription factor. PML Cell. 1991;66:663\u201374.","journal-title":"PML Cell"},{"key":"1721_CR180","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/S0092-8674(02)00626-8","volume":"108","author":"P Salomoni","year":"2002","unstructured":"Salomoni P, Pandolfi PP. The role of PML in tumor suppression. Cell. 2002;108:165\u201370.","journal-title":"Cell"},{"key":"1721_CR181","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S1097-2765(00)80322-6","volume":"5","author":"RJ Lin","year":"2000","unstructured":"Lin RJ, Evans RM. Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell. 2000;5:821\u201330.","journal-title":"Mol Cell"},{"key":"1721_CR182","doi-asserted-by":"publisher","first-page":"3110","DOI":"10.1038\/sj.onc.1204336","volume":"20","author":"S Minucci","year":"2001","unstructured":"Minucci S, Nervi C, Lo Coco F, Pelicci PG. Histone deacetylases: a common molecular target for differentiation treatment of acute myeloid leukemias? Oncogene. 2001;20:3110\u20135.","journal-title":"Oncogene"},{"key":"1721_CR183","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1062524","volume":"12","author":"SG Iyer","year":"2022","unstructured":"Iyer SG, Elias L, Stanchina M, Watts J. The treatment of acute promyelocytic leukemia in 2023: paradigm, advances, and future directions. Front Oncol. 2022;12:1062524.","journal-title":"Front Oncol"},{"key":"1721_CR184","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1159\/000507805","volume":"64","author":"C Gurnari","year":"2020","unstructured":"Gurnari C, De Bellis E, Divona M, Ottone T, Lavorgna S, Voso MT. When poisons cure: the case of arsenic in acute promyelocytic leukemia. Chemotherapy. 2020;64:238\u201347.","journal-title":"Chemotherapy"},{"key":"1721_CR185","doi-asserted-by":"publisher","first-page":"142","DOI":"10.2991\/chi.k.210703.001","volume":"3","author":"MA Sanz","year":"2021","unstructured":"Sanz MA, Barragan E. History of acute promyelocytic leukemia. Clin Hematol Int. 2021;3:142\u201352.","journal-title":"Clin Hematol Int"},{"key":"1721_CR186","first-page":"170","volume":"12","author":"H Sun","year":"1992","unstructured":"Sun H, Ma L, Hu X, Zhang T. Treatment of acute promylocytic leukemia by AiLing-1 therapy. Zhong Xi Yi Jie He Xue Bao. 1992;12:170\u20132.","journal-title":"Zhong Xi Yi Jie He Xue Bao"},{"key":"1721_CR187","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1056\/NEJM199811053391901","volume":"339","author":"SL Soignet","year":"1998","unstructured":"Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998;339:1341\u20138.","journal-title":"N Engl J Med"},{"key":"1721_CR188","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1200\/JCO.2001.19.18.3852","volume":"19","author":"SL Soignet","year":"2001","unstructured":"Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001;19:3852\u201360.","journal-title":"J Clin Oncol"},{"key":"1721_CR189","doi-asserted-by":"publisher","first-page":"5328","DOI":"10.1073\/pnas.0400053101","volume":"101","author":"ZX Shen","year":"2004","unstructured":"Shen ZX, Shi ZZ, Fang J, et al. All-trans retinoic acid\/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004;101:5328\u201335.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1721_CR190","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/annonc\/mdj019","volume":"17","author":"A Ghavamzadeh","year":"2006","unstructured":"Ghavamzadeh A, Alimoghaddam K, Ghaffari SH, et al. Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and\/or chemotherapy. Ann Oncol. 2006;17:131\u20134.","journal-title":"Ann Oncol"},{"key":"1721_CR191","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1182\/blood-2005-08-3532","volume":"107","author":"V Mathews","year":"2006","unstructured":"Mathews V, George B, Lakshmi KM, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006;107:2627\u201332.","journal-title":"Blood"},{"key":"1721_CR192","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2005-10-4006","volume":"107","author":"E Estey","year":"2006","unstructured":"Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107:3469\u201373.","journal-title":"Blood"},{"key":"1721_CR193","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111\u201321.","journal-title":"N Engl J Med"},{"key":"1721_CR194","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/S1470-2045(15)00193-X","volume":"16","author":"AK Burnett","year":"2015","unstructured":"Burnett AK, Russell NH, Hills RK, et al. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncol. 2015;16:1295\u2013305.","journal-title":"Lancet Oncol"},{"key":"1721_CR195","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1182\/blood-2016-09-736686","volume":"129","author":"Y Abaza","year":"2017","unstructured":"Abaza Y, Kantarjian H, Garcia-Manero G, et al. Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and Gemtuzumab. Blood. 2017;129:1275\u201383.","journal-title":"Blood"},{"key":"1721_CR196","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.3748\/wjg.v20.i11.2751","volume":"20","author":"JB Park","year":"2014","unstructured":"Park JB, Koo JS. Helicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphoma. World J Gastroenterol. 2014;20:2751\u20139.","journal-title":"World J Gastroenterol"},{"key":"1721_CR197","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/S0140-6736(95)90113-2","volume":"345","author":"E Bayerdorffer","year":"1995","unstructured":"Bayerdorffer E, Neubauer A, Rudolph B, et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT lymphoma study group. Lancet. 1995;345:1591\u20134.","journal-title":"Lancet"},{"key":"1721_CR198","doi-asserted-by":"publisher","first-page":"767","DOI":"10.7326\/0003-4819-122-10-199505150-00006","volume":"122","author":"E Roggero","year":"1995","unstructured":"Roggero E, Zucca E, Pinotti G, et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med. 1995;122:767\u20139.","journal-title":"Ann Intern Med"},{"key":"1721_CR199","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2165\/00002018-199921030-00002","volume":"21","author":"JM Lary","year":"1999","unstructured":"Lary JM, Daniel KL, Erickson JD, Roberts HE, Moore CA. The return of thalidomide: can birth defects be prevented? Drug Saf. 1999;21:161\u20139.","journal-title":"Drug Saf"},{"key":"1721_CR200","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1007\/s00109-016-1450-z","volume":"94","author":"S Lindner","year":"2016","unstructured":"Lindner S, Kronke J. The molecular mechanism of thalidomide analogs in hematologic malignancies. J Mol Med (Berl). 2016;94:1327\u201334.","journal-title":"J Mol Med (Berl)"},{"key":"1721_CR201","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565\u201371.","journal-title":"N Engl J Med"},{"key":"1721_CR202","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.juro.2008.11.026","volume":"181","author":"WD Figg","year":"2009","unstructured":"Figg WD, Hussain MH, Gulley JL, et al. A double-blind randomized crossover study of oral thalidomide versus placebo for androgen dependent prostate cancer treated with intermittent androgen ablation. J Urol. 2009;181:1104\u201313. discussion 13.","journal-title":"J Urol"},{"key":"1721_CR203","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000336481","volume":"5","author":"JM Gasent Blesa","year":"2012","unstructured":"Gasent Blesa JM, Godoy MP, Esparcia MF, et al. PSA response to Lenalidomide therapy in a pre-treated patient with metastatic prostate cancer refractory to hormones and chemotherapy: a case report. Case Rep Oncol. 2012;5:181\u20136.","journal-title":"Case Rep Oncol"},{"key":"1721_CR204","doi-asserted-by":"publisher","first-page":"A43","DOI":"10.1158\/1078-0432.TCMUSA10-A43","volume":"16","author":"JY Henry","year":"2016","unstructured":"Henry JY, Lu L, Adams M, Meyer B, Bartlett B, Dalgleish AG. Abstract A43: Lenalidomide enhances the anti-proliferative activity of docetaxel in in vivo and in vitro models of prostate cancer. Clin Cancer Res. 2016;16:A43\u2013A.","journal-title":"Clin Cancer Res"},{"key":"1721_CR205","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/S1470-2045(15)70025-2","volume":"16","author":"DP Petrylak","year":"2015","unstructured":"Petrylak DP, Vogelzang NJ, Budnik N, et al. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2015;16:417\u201325.","journal-title":"Lancet Oncol"},{"key":"1721_CR206","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0049-3848(03)00379-7","volume":"110","author":"JR Vane","year":"2003","unstructured":"Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res. 2003;110:255\u20138.","journal-title":"Thromb Res"},{"key":"1721_CR207","doi-asserted-by":"publisher","first-page":"6007","DOI":"10.1007\/s13277-015-4438-3","volume":"37","author":"G Ai","year":"2016","unstructured":"Ai G, Dachineni R, Kumar DR, Marimuthu S, Alfonso LF, Bhat GJ. Aspirin acetylates wild type and mutant p53 in colon cancer cells: identification of aspirin acetylated sites on recombinant p53. Tumour Biol. 2016;37:6007\u201316.","journal-title":"Tumour Biol"},{"key":"1721_CR208","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1093\/carcin\/bgw042","volume":"37","author":"Y Guo","year":"2016","unstructured":"Guo Y, Liu Y, Zhang C, et al. The epigenetic effects of aspirin: the modification of histone H3 lysine 27 acetylation in the prevention of colon carcinogenesis in azoxymethane- and dextran sulfate sodium-treated CF-1 mice. Carcinogenesis. 2016;37:616\u201324.","journal-title":"Carcinogenesis"},{"key":"1721_CR209","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-020-01884-4","volume":"11","author":"X Zhang","year":"2020","unstructured":"Zhang X, Du R, Luo N, Xiang R, Shen W. Aspirin mediates histone methylation that inhibits inflammation-related stemness gene expression to diminish cancer stemness via COX-independent manner. Stem Cell Res Ther. 2020;11:370.","journal-title":"Stem Cell Res Ther"},{"key":"1721_CR210","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/S2468-1253(21)00018-2","volume":"6","author":"H Ishikawa","year":"2021","unstructured":"Ishikawa H, Mutoh M, Sato Y, et al. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with Familial adenomatous polyposis without previous colectomy (J-FAPP study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial. Lancet Gastroenterol Hepatol. 2021;6:474\u201381.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1721_CR211","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1136\/ard.23.3.226","volume":"23","author":"JS Percy","year":"1964","unstructured":"Percy JS, Stephenson P, Thompson M. Indomethacin in the treatment of rheumatic diseases. Ann Rheum Dis. 1964;23:226\u201331.","journal-title":"Ann Rheum Dis"},{"key":"1721_CR212","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1042\/BJ20111236","volume":"443","author":"C Brunelli","year":"2012","unstructured":"Brunelli C, Amici C, Angelini M, Fracassi C, Belardo G, Santoro MG. The non-steroidal anti-inflammatory drug indomethacin activates the eIF2alpha kinase PKR, causing a translational block in human colorectal cancer cells. Biochem J. 2012;443:379\u201386.","journal-title":"Biochem J"},{"key":"1721_CR213","doi-asserted-by":"publisher","first-page":"e472","DOI":"10.1016\/S1470-2045(17)30536-3","volume":"18","author":"J Cuzick","year":"2017","unstructured":"Cuzick J. Preventive therapy for cancer. Lancet Oncol. 2017;18:e472\u201382.","journal-title":"Lancet Oncol"},{"key":"1721_CR214","doi-asserted-by":"publisher","first-page":"376","DOI":"10.7326\/0003-4819-146-5-200703060-00010","volume":"146","author":"A Rostom","year":"2007","unstructured":"Rostom A, Dube C, Lewin G, et al. Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. preventive services task force. Ann Intern Med. 2007;146:376\u201389.","journal-title":"Ann Intern Med"},{"key":"1721_CR215","unstructured":"Basquez R, Pippin MM. Prazosin. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Micah Pippin declares no relevant financial relationships with ineligible companies. 2024."},{"key":"1721_CR216","first-page":"23","volume":"55","author":"TJ Martin","year":"1978","unstructured":"Martin TJ, Nahorski SR, Hunt NH, Dawborn JK, Loomes RS, Underwood CE. Characterization of beta-adrenergic receptor linked to adenylate cyclase in a human cancer cell line (COLO 16). Clin Sci Mol Med. 1978;55:23\u20139.","journal-title":"Clin Sci Mol Med"},{"key":"1721_CR217","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1001\/archoto.2011.55","volume":"137","author":"C Fuchsmann","year":"2011","unstructured":"Fuchsmann C, Quintal M-C, Giguere C, et al. Propranolol as first-line treatment of head and neck hemangiomas. Arch Otolaryngol Head Neck Surg. 2011;137:471\u20138.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"1721_CR218","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.113974","author":"A Embaby","year":"2024","unstructured":"Embaby A, Heinhuis KM, Ijzerman NS, et al. Propranolol monotherapy in angiosarcoma\u2013 a window-of-opportunity study (PropAngio). Eur J Cancer. 2024. https:\/\/doi.org\/10.1016\/j.ejca.2024.113974.","journal-title":"Eur J Cancer"},{"key":"1721_CR219","unstructured":"Patel PH, Hashmi MF. Macrolides. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Muhammad Hashmi declares no relevant financial relationships with ineligible companies. 2024."},{"key":"1721_CR220","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000048556","volume":"47","author":"M Sakamoto","year":"2001","unstructured":"Sakamoto M, Mikasa K, Majima T, et al. Anti-cachectic effect of clarithromycin for patients with unresectable non-small cell lung cancer. Chemotherapy. 2001;47:444\u201351.","journal-title":"Chemotherapy"},{"key":"1721_CR221","first-page":"213","volume-title":"Chapter 9 - Phytodrugs and immunomodulators for the therapy of leishmaniasis","author":"CB Naman","year":"2018","unstructured":"Naman CB, Gomes CM, Gupta G. In: Mandal SC, Mandal V, Konishi T, editors. Chapter 9 - Phytodrugs and immunomodulators for the therapy of leishmaniasis. Natural Products and Drug Discovery: Elsevier; 2018. pp. 213\u201375."},{"key":"1721_CR222","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1080\/00034983.1994.11812832","volume":"88","author":"ALD Yarbuh","year":"1994","unstructured":"Yarbuh ALD, A\u00f1ez N, Pe\u00f1a YPD, Burguera JL, Burguera M. Antimony determination in tissues and serum of hamsters infected with leishmania garnhami and treated with Meglumine antimoniate. Ann Trop Med Parasitol. 1994;88:37\u201341.","journal-title":"Ann Trop Med Parasitol"},{"key":"1721_CR223","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1093\/jnci\/53.2.469","volume":"53","author":"C Jasmin","year":"1974","unstructured":"Jasmin C, Chermann JC, Herve G, et al. In vivo inhibition of murine leukemia and sarcoma viruses by the heteropolyanion 5-tungsto-2-antimoniate. J Natl Cancer Inst. 1974;53:469\u201374.","journal-title":"J Natl Cancer Inst"},{"issue":"Suppl 1","key":"1721_CR224","doi-asserted-by":"publisher","first-page":"27","DOI":"10.2165\/00003495-200161001-00003","volume":"61","author":"K De Beule","year":"2001","unstructured":"De Beule K, Van Gestel J. Pharmacology of itraconazole. Drugs. 2001;61(Suppl 1):27\u201337.","journal-title":"Drugs"},{"key":"1721_CR225","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/0008-5472.CAN-10-0259","volume":"70","author":"I Ringshausen","year":"2010","unstructured":"Ringshausen I, Feuerstacke Y, Krainz P, et al. Antifungal therapy with Itraconazole impairs the anti-lymphoma effects of rituximab by inhibiting recruitment of CD20 to cell surface lipid rafts. Cancer Res. 2010;70:4292\u20136.","journal-title":"Cancer Res"},{"key":"1721_CR226","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0125180","volume":"10","author":"BR Yang","year":"2015","unstructured":"Yang BR, Seong JM, Choi NK, et al. Co-medication of statins with contraindicated drugs. PLoS ONE. 2015;10:e0125180.","journal-title":"PLoS ONE"},{"key":"1721_CR227","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/0169-4758(90)90227-U","volume":"6","author":"E Lacey","year":"1990","unstructured":"Lacey E. Mode of action of benzimidazoles. Parasitol Today. 1990;6:112\u20135.","journal-title":"Parasitol Today"},{"key":"1721_CR228","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/0304-4165(80)90431-6","volume":"630","author":"PA Friedman","year":"1980","unstructured":"Friedman PA, Platzer EG. Interaction of anthelmintic benzimidazoles with Ascaris suum embryonic tubulin. Biochim Biophys Acta. 1980;630:271\u20138.","journal-title":"Biochim Biophys Acta"},{"key":"1721_CR229","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/CMAR.S44261","volume":"6","author":"AA Argyriou","year":"2014","unstructured":"Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res. 2014;6:135\u201347.","journal-title":"Cancer Manag Res"},{"key":"1721_CR230","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1007\/s00280-007-0538-0","volume":"61","author":"D Martarelli","year":"2008","unstructured":"Martarelli D, Pompei P, Baldi C, Mazzoni G. Mebendazole inhibits growth of human adrenocortical carcinoma cell lines implanted in nude mice. Cancer Chemother Pharmacol. 2008;61:809\u201317.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1721_CR231","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3892\/ol.2021.12656","volume":"21","author":"U Kim","year":"2021","unstructured":"Kim U, Shin C, Kim CY, et al. Albendazole exerts antiproliferative effects on prostate cancer cells by inducing reactive oxygen species generation. Oncol Lett. 2021;21:395.","journal-title":"Oncol Lett"},{"key":"1721_CR232","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.670804","volume":"11","author":"YQ Li","year":"2021","unstructured":"Li YQ, Zheng Z, Liu QX, et al. Repositioning of antiparasitic drugs for tumor treatment. Front Oncol. 2021;11:670804.","journal-title":"Front Oncol"},{"key":"1721_CR233","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1056\/NEJM199609053351007","volume":"335","author":"CS Crumpacker","year":"1996","unstructured":"Crumpacker CS, Ganciclovir. N Engl J Med. 1996;335:721\u20139.","journal-title":"N Engl J Med"},{"key":"1721_CR234","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2165\/00003495-200666090-00012","volume":"66","author":"V Oldfield","year":"2006","unstructured":"Oldfield V, Plosker GL. Lopinavir\/ritonavir: a review of its use in the management of HIV infection. Drugs. 2006;66:1275\u201399.","journal-title":"Drugs"},{"key":"1721_CR235","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1747-0285.2008.00647.x","volume":"71","author":"ET Brower","year":"2008","unstructured":"Brower ET, Bacha UM, Kawasaki Y, Freire E. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem Biol Drug Des. 2008;71:298\u2013305.","journal-title":"Chem Biol Drug Des"},{"key":"1721_CR236","unstructured":"Kemnic TR, Gulick PG. HIV Antiretroviral Therapy. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Peter Gulick declares no relevant financial relationships with ineligible companies. 2024."},{"key":"1721_CR237","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1111\/j.1478-3231.2008.01896.x","volume":"28","author":"WP Hofmann","year":"2008","unstructured":"Hofmann WP, Herrmann E, Sarrazin C, Zeuzem S. Ribavirin mode of action in chronic hepatitis C: from clinical use back to molecular mechanisms. Liver Int. 2008;28:1332\u201343.","journal-title":"Liver Int"},{"key":"1721_CR238","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1038\/leu.2011.57","volume":"25","author":"BC Kraljacic","year":"2011","unstructured":"Kraljacic BC, Arguello M, Amri A, Cormack G, Borden K. Inhibition of eIF4E with ribavirin cooperates with common chemotherapies in primary acute myeloid leukemia specimens. Leukemia. 2011;25:1197\u2013200.","journal-title":"Leukemia"},{"key":"1721_CR239","doi-asserted-by":"publisher","first-page":"2749","DOI":"10.1007\/s00436-020-06786-1","volume":"119","author":"JO Adebayo","year":"2020","unstructured":"Adebayo JO, Tijjani H, Adegunloye AP, Ishola AA, Balogun EA, Malomo SO. Enhancing the antimalarial activity of Artesunate. Parasitol Res. 2020;119:2749\u201364.","journal-title":"Parasitol Res"},{"key":"1721_CR240","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jphs.2018.09.011","volume":"138","author":"Z Fei","year":"2018","unstructured":"Fei Z, Gu W, Xie R, Su H, Jiang Y. Artesunate enhances radiosensitivity of esophageal cancer cells by inhibiting the repair of DNA damage. J Pharmacol Sci. 2018;138:131\u20137.","journal-title":"J Pharmacol Sci"},{"key":"1721_CR241","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.bbrc.2019.09.023","volume":"519","author":"N Wang","year":"2019","unstructured":"Wang N, Zeng GZ, Yin JL, Bian ZX. Artesunate activates the ATF4-CHOP-CHAC1 pathway and affects ferroptosis in burkitt\u2019s lymphoma. Biochem Biophys Res Commun. 2019;519:533\u20139.","journal-title":"Biochem Biophys Res Commun"},{"key":"1721_CR242","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/s41401-020-0478-3","volume":"42","author":"ZJ Li","year":"2021","unstructured":"Li ZJ, Dai HQ, Huang XW, et al. Artesunate synergizes with Sorafenib to induce ferroptosis in hepatocellular carcinoma. Acta Pharmacol Sin. 2021;42:301\u201310.","journal-title":"Acta Pharmacol Sin"},{"key":"1721_CR243","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/s41584-020-0372-x","volume":"16","author":"E Schrezenmeier","year":"2020","unstructured":"Schrezenmeier E, D\u00f6rner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020;16:155\u201366.","journal-title":"Nat Rev Rheumatol"},{"key":"1721_CR244","doi-asserted-by":"publisher","first-page":"781","DOI":"10.3332\/ecancer.2017.781","volume":"11","author":"C Verbaanderd","year":"2017","unstructured":"Verbaanderd C, Maes H, Schaaf MB, et al. Repurposing drugs in oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents. Ecancermedicalscience. 2017;11:781.","journal-title":"Ecancermedicalscience"},{"key":"1721_CR245","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/nrclinonc.2011.71","volume":"8","author":"F Janku","year":"2011","unstructured":"Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol. 2011;8:528\u201339.","journal-title":"Nat Rev Clin Oncol"},{"key":"1721_CR246","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1093\/neuonc\/nop046","volume":"12","author":"EL Kim","year":"2010","unstructured":"Kim EL, Wustenberg R, Rubsam A, et al. Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells. Neuro Oncol. 2010;12:389\u2013400.","journal-title":"Neuro Oncol"},{"key":"1721_CR247","doi-asserted-by":"publisher","first-page":"13949","DOI":"10.1073\/pnas.240464697","volume":"97","author":"NS Kane","year":"2000","unstructured":"Kane NS, Hirschberg B, Qian S, et al. Drug-resistant drosophila indicate glutamate-gated chloride channels are targets for the antiparasitics nodulisporic acid and Ivermectin. Proc Natl Acad Sci U S A. 2000;97:13949\u201354.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1721_CR248","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1073\/pnas.76.4.2062","volume":"76","author":"LC Fritz","year":"1979","unstructured":"Fritz LC, Wang CC, Gorio A. Avermectin B1a irreversibly blocks postsynaptic potentials at the Lobster neuromuscular junction by reducing muscle membrane resistance. Proc Natl Acad Sci U S A. 1979;76:2062\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1721_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105207","volume":"163","author":"M Tang","year":"2021","unstructured":"Tang M, Hu X, Wang Y, et al. Ivermectin, a potential anticancer drug derived from an antiparasitic drug. Pharmacol Res. 2021;163:105207.","journal-title":"Pharmacol Res"},{"key":"1721_CR250","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1158\/1535-7163.MCT-14-0980-T","volume":"14","author":"YJ Kwon","year":"2015","unstructured":"Kwon YJ, Petrie K, Leibovitch BA, et al. Selective inhibition of SIN3 corepressor with avermectins as a novel therapeutic strategy in Triple-Negative breast cancer. Mol Cancer Ther. 2015;14:1824\u201336.","journal-title":"Mol Cancer Ther"},{"key":"1721_CR251","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1172\/JCI130819","volume":"130","author":"L Nappi","year":"2020","unstructured":"Nappi L, Aguda AH, Nakouzi NA, et al. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest. 2020;130:699\u2013714.","journal-title":"J Clin Invest"},{"key":"1721_CR252","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/cmdc.201800100","volume":"13","author":"H Kadri","year":"2018","unstructured":"Kadri H, Lambourne OA, Mehellou Y. Niclosamide, a drug with many (Re)purposes. ChemMedChem. 2018;13:1088\u201391.","journal-title":"ChemMedChem"},{"key":"1721_CR253","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1289\/ehp.9087213","volume":"87","author":"H Terada","year":"1990","unstructured":"Terada H. Uncouplers of oxidative phosphorylation. Environ Health Perspect. 1990;87:213\u20138.","journal-title":"Environ Health Perspect"},{"key":"1721_CR254","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1017\/S0022149X00028042","volume":"58","author":"NA Pampori","year":"1984","unstructured":"Pampori NA, Singh G, Srivastava VM. Cotugnia digonopora: carbohydrate metabolism and effect of anthelmintics on immature worms. J Helminthol. 1984;58:39\u201347.","journal-title":"J Helminthol"},{"key":"1721_CR255","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.canlet.2017.03.022","volume":"397","author":"C Guo","year":"2017","unstructured":"Guo C, Yeh S, Niu Y, et al. Targeting androgen receptor versus targeting androgens to suppress castration resistant prostate cancer. Cancer Lett. 2017;397:133\u201343.","journal-title":"Cancer Lett"},{"key":"1721_CR256","unstructured":"Pino MA, Azer SA. Cimetidine. StatPearls. Treasure Island (FL) ineligible companies. Disclosure: Samy Azer declares no relevant financial relationships with ineligible companies.2024."},{"key":"1721_CR257","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1038\/bjc.1981.99","volume":"43","author":"C Burtin","year":"1981","unstructured":"Burtin C, Scheinmann P, Salomon JC, et al. Increased tissue histamine in tumour-bearing mice and rats. Br J Cancer. 1981;43:684\u20138.","journal-title":"Br J Cancer"},{"key":"1721_CR258","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/bjc.1983.55","volume":"47","author":"C Burtin","year":"1983","unstructured":"Burtin C, Noirot C, Paupe J, Scheinmann P. Decreased blood histamine levels in patients with solid malignant tumours. Br J Cancer. 1983;47:367\u201372.","journal-title":"Br J Cancer"},{"key":"1721_CR259","first-page":"638","volume":"59","author":"ET Creagan","year":"1987","unstructured":"Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM. Three consecutive phase II studies of Recombinant interferon alfa-2a in advanced malignant melanoma. Updated Analyses Cancer. 1987;59:638\u201346.","journal-title":"Updated Analyses Cancer"},{"key":"1721_CR260","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1097\/00008390-200010010-00009","volume":"10","author":"H Schmidt","year":"2000","unstructured":"Schmidt H, Geertsen PF, Fode K, Rytter C, Bastholt L, von der Maase H. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: a phase II study. Melanoma Res. 2000;10:66\u201377.","journal-title":"Melanoma Res"},{"key":"1721_CR261","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00125-017-4342-z","volume":"60","author":"G Rena","year":"2017","unstructured":"Rena G, Hardie DG, Pearson ER. The mechanisms of action of Metformin. Diabetologia. 2017;60:1577\u201385.","journal-title":"Diabetologia"},{"key":"1721_CR262","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1008862","volume":"364","author":"S Rao Kondapally Seshasai","year":"2011","unstructured":"Rao Kondapally Seshasai S, Kaptoge S, Thompson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med. 2011;364:829\u201341.","journal-title":"N Engl J Med"},{"key":"1721_CR263","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1152\/physrev.00030.2014","volume":"95","author":"EJ Gallagher","year":"2015","unstructured":"Gallagher EJ, LeRoith D. Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev. 2015;95:727\u201348.","journal-title":"Physiol Rev"},{"key":"1721_CR264","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nm.3596","volume":"20","author":"M Pollak","year":"2014","unstructured":"Pollak M. Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment. Nat Med. 2014;20:591\u20133.","journal-title":"Nat Med"},{"key":"1721_CR265","doi-asserted-by":"publisher","first-page":"e2100344","DOI":"10.1200\/PO.21.00344","volume":"6","author":"E Remenar","year":"2022","unstructured":"Remenar E, Doczi R, Dirner A, et al. Lasting complete clinical response of a recurring cutaneous squamous cell carcinoma with MEK mutation and PIK3CA amplification achieved by dual Trametinib and Metformin therapy. JCO Precis Oncol. 2022;6:e2100344.","journal-title":"JCO Precis Oncol"},{"key":"1721_CR266","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.cmet.2016.09.005","volume":"24","author":"X Liu","year":"2016","unstructured":"Liu X, Romero IL, Litchfield LM, Lengyel E, Locasale JW. Metformin targets central carbon metabolism and reveals mitochondrial requirements in human cancers. Cell Metab. 2016;24:728\u201339.","journal-title":"Cell Metab"},{"key":"1721_CR267","unstructured":"Sizar O, Khare S, Jamil RT, Talati R. Statin medications. Treasure Island (FL):\u00a0StatPearls. ineligible companies: Medications. StatPearls; 2024.\u00a0Ineligible companies. Disclosure: Swapnil Khare declares no relevant financial relationships with ineligible companies. Disclosure: Radia Jamil declares no relevant financial relationships with ineligible companies. Disclosure: Raja Talati declares no relevant financial relationships with ineligible companies"},{"key":"1721_CR268","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10549-013-2473-6","volume":"138","author":"O Bjarnadottir","year":"2013","unstructured":"Bjarnadottir O, Romero Q, Bendahl PO, et al. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. Breast Cancer Res Treat. 2013;138:499\u2013508.","journal-title":"Breast Cancer Res Treat"},{"key":"1721_CR269","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ejca.2004.12.013","volume":"41","author":"JJ Knox","year":"2005","unstructured":"Knox JJ, Siu LL, Chen E, et al. A phase I trial of prolonged administration of Lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix. Eur J Cancer. 2005;41:523\u201330.","journal-title":"Eur J Cancer"},{"key":"1721_CR270","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1182\/blood-2006-08-044446","volume":"109","author":"SM Kornblau","year":"2007","unstructured":"Kornblau SM, Banker DE, Stirewalt D, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of Pravastatin to idarubicin\u2009+\u2009high-dose Ara-C: a phase 1 study. Blood. 2007;109:2999\u20133006.","journal-title":"Blood"},{"key":"1721_CR271","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00277-011-1276-2","volume":"90","author":"M Hus","year":"2011","unstructured":"Hus M, Grzasko N, Szostek M, et al. Thalidomide, dexamethasone and Lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma. Ann Hematol. 2011;90:1161\u20136.","journal-title":"Ann Hematol"},{"key":"1721_CR272","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12967-016-0836-6","volume":"14","author":"GD Goss","year":"2016","unstructured":"Goss GD, Jonker DJ, Laurie SA, et al. A phase I study of high-dose Rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies. J Transl Med. 2016;14:83.","journal-title":"J Transl Med"},{"key":"1721_CR273","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1200\/JCO.2016.69.7391","volume":"35","author":"MJ Seckl","year":"2017","unstructured":"Seckl MJ, Ottensmeier CH, Cullen M, Multicenter, Phase III, Randomized, et al. Double-Blind, Placebo-Controlled trial of Pravastatin added to First-Line standard chemotherapy in Small-Cell lung cancer (LUNGSTAR). J Clin Oncol. 2017;35:1506\u201314.","journal-title":"J Clin Oncol"},{"key":"1721_CR274","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/bjc.2015.371","volume":"113","author":"SH Lim","year":"2015","unstructured":"Lim SH, Kim TW, Hong YS, et al. A randomised, double-blind, placebo-controlled multi-centre phase III trial of XELIRI\/FOLFIRI plus Simvastatin for patients with metastatic colorectal cancer. Br J Cancer. 2015;113:1421\u20136.","journal-title":"Br J Cancer"},{"key":"1721_CR275","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2019.04.021","volume":"71","author":"JL Jouve","year":"2019","unstructured":"Jouve JL, Lecomte T, Bouche O, et al. Pravastatin combination with Sorafenib does not improve survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:516\u201322.","journal-title":"J Hepatol"},{"key":"1721_CR276","doi-asserted-by":"publisher","first-page":"2822","DOI":"10.1016\/j.ejca.2014.08.005","volume":"50","author":"ST Kim","year":"2014","unstructured":"Kim ST, Kang JH, Lee J, et al. Simvastatin plus capecitabine-cisplatin versus placebo plus capecitabine-cisplatin in patients with previously untreated advanced gastric cancer: a double-blind randomised phase 3 study. Eur J Cancer. 2014;50:2822\u201330.","journal-title":"Eur J Cancer"},{"key":"1721_CR277","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.4065\/83.9.1032","volume":"83","author":"MT Drake","year":"2008","unstructured":"Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032\u201345.","journal-title":"Mayo Clin Proc"},{"key":"1721_CR278","first-page":"1807","volume":"30","author":"B Rack","year":"2010","unstructured":"Rack B, Juckstock J, Genss EM, et al. Effect of zoledronate on persisting isolated tumour cells in patients with early breast cancer. Anticancer Res. 2010;30:1807\u201313.","journal-title":"Anticancer Res"},{"key":"1721_CR279","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1200\/jco.2008.26.15_suppl.559","volume":"26","author":"AY Lin","year":"2008","unstructured":"Lin AY, Park JW, Scott J, et al. Zoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow. J Clin Oncol. 2008;26:559.","journal-title":"J Clin Oncol"},{"key":"1721_CR280","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1200\/jco.2012.30.15_suppl.502","volume":"30","author":"H Marshall","year":"2012","unstructured":"Marshall H, Gregory W, Bell R, et al. Adjuvant therapy with Zoledronic acid (AZURE-BIG 01\/04): the influence of menopausal status and age on treatment effects. J Clin Oncol. 2012;30:502.","journal-title":"J Clin Oncol"},{"key":"1721_CR281","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1177\/1758834011420599","volume":"3","author":"M Gnant","year":"2011","unstructured":"Gnant M. Zoledronic acid in breast cancer: latest findings and interpretations. Ther Adv Med Oncol. 2011;3:293\u2013301.","journal-title":"Ther Adv Med Oncol"},{"issue":"14","key":"1721_CR282","doi-asserted-by":"publisher","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-08-0024","volume":"14","author":"N Dhillon","year":"2008","unstructured":"Dhillon N, Aggarwal BB, Newman RA, et al. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14(14):4491\u20139.","journal-title":"Clin Cancer Res"},{"key":"1721_CR283","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/cncr.21216","volume":"104","author":"DR Siwak","year":"2005","unstructured":"Siwak DR, Shishodia S, Aggarwal BB, Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappab activity and are independent of the B-Raf\/mitogen-activated\/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer. 2005;104:879\u201390.","journal-title":"Cancer"},{"key":"1721_CR284","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1002\/cncr.21300","volume":"104","author":"L Li","year":"2005","unstructured":"Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005;104:1322\u201331.","journal-title":"Cancer"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01721-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11912-025-01721-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-025-01721-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T06:03:03Z","timestamp":1765432983000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11912-025-01721-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":284,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1721"],"URL":"https:\/\/doi.org\/10.1007\/s11912-025-01721-y","relation":{},"ISSN":["1534-6269"],"issn-type":[{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kurzrock has received research funding from Boehringer Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda, and TopAlliance and from the NCI; as well as consultant and\/or speaker fees and\/or advisory board\/consultant for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Inc., Biological Dynamics, Caris, Datar Cancer Genetics, Daiichi, EISAI, EOM Pharmaceuticals, Iylon, LabCorp, Merck, NeoGenomics, Neomed, Pfizer, Precirix, Prosperdtx, Regeneron, Roche, TD2\/Volastra, Turning Point Therapeutics, X-Biotech; has an equity interest in CureMatch Inc.; serves on the Board of CureMatch and CureMetrix, and is a co-founder of CureMatch. Dr. Munoz reports the following COI: Consulting \u2013 Pharmacyclics\/Abbvie, Bayer, Gilead\/Kite, Beigene, Pfizer, Janssen, Celgene\/BMS, Kyowa, Alexion, Fosunkite, Seattle Genetics, Karyopharm, Aurobindo, Verastem, Genmab, Genzyme, Genentech\/Roche, ADC Therapeutics, Epizyme, Beigene, Novartis, Morphosys\/Incyte, MEI, TG Therapeutics, AstraZeneca, Eli Lilly; Research funding \u2013 Bayer, Gilead\/Kite, Celgene, Merck, Portola, Incyte, Genentech, Pharmacyclics, Seattle Genetics, Janssen, Millennium, Novartis, Beigene. Honoraria - Targeted Oncology, OncView, Curio, and Physicians\u2019 Education Resource. Dr. Desphande does not report COI.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}